ClinicalTrials.gg
Not yet recruitingNCT07941622Updated Nov 17, 2026

Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.

A Phase 3 interventional study of DTaP-IPV-HB-PRP~T combined vaccine and DTaP-IPV//PRP~T combined vaccine in Haemophilus Influenzae Type b Immunisation, Hepatitis B Immunisation and Polio Immunization, sponsored by Sanofi. Not yet recruiting. Open to participants aged 30 Days to 45 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
30 Days to 45 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diphtheria by Sanofi — 1 open to participants now, 1 under way, 1 of them phase 3. Diphtheria · Sanofi.

Planned enrollment
32nd of 75
720 · median 600
Started
2026
the only one that year
Phase 3
46 of 81
1 open now
Registered
81st of 81
by date

Among the 81 studies in Diphtheria by Sanofi, this one is the 32nd largest by planned enrollment of the 75 interventional ones that give a count, is the only one that started in 2026, is one of 46 in phase 3, and was the 81st registered.

Diphtheria

268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.

Browse Diphtheria studies →

Open to participants now

1 of the 81 studies in Diphtheria by Sanofi is open now.

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 30 Days to 45 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diphtheria by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.

Study details include:

  • The study duration per participant will be approximately 18 months.
  • The study vaccines administration:
  • Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA.
  • Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.
03

Conditions studied

  • Haemophilus Influenzae Type b Immunisation
  • Hepatitis B Immunisation
  • Polio Immunization
  • Pertussis Immunisation
  • Diphtheria Immunisation
  • Tetanus Immunisation
  • Healthy Volunteers
04

Who can participate

Ages eligible
30 Days to 45 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine
  • Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, and in both cases medically stable as assessed by the investigator
  • Participants who are born to mothers with documented seronegative status
  • form has been signed and dated by the parent(s) or other LAR
  • Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • Known/suspected immunodeficiency; therapy since birth; long-term systemic therapy
  • History of diagnosis of , diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection
  • History of seizure or significant stable or progressive neurological disorders
  • Known systemic to any study intervention components, or history of a life-threatening reaction to study interventions or product with the same substances
  • Known thrombocytopenia
  • Bleeding disorder
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Any vaccine given since birth or planned receipt of any vaccine until 1 month after the completion of the primary series vaccination with the study interventions except for Bacille Calmette-Guérin (BCG) vaccine and meningococcal polysaccharide vaccine-A.
  • Previous vaccination against D, T, pertussis, poliomyelitis, Hep B (except the dose of Hep B given at birth) or Haemophilus influenzae type b infections (since birth) with an or marketed vaccine.
  • Receipt of immune globulins, blood or blood-derived products
  • Participation in another clinical study for a vaccine, drug, medical device, or medical procedure at the time of study enrollment or planned participation during the present study period.
  • Known personal or maternal history of or seropositivity
  • Being in an emergency setting
  • Identified as a natural or adopted child of the Investigator/study site employee with direct involvement in the study

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
720 participants (estimated)

Study arms

  • Experimental
    Group 1 (the investigational group)

    Hexaxim at 2, 4 and 6 MoA

    Biological: DTaP-IPV-HB-PRP~T combined vaccine

  • Active comparator
    Group 2 (the comparator group)

    Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA

    Biological: DTaP-IPV//PRP~T combined vaccine · Biological: monovalent Hep B vaccine

Interventions

  • BiologicalDTaP-IPV-HB-PRP~T combined vaccine

    Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection

  • BiologicalDTaP-IPV//PRP~T combined vaccine

    Pharmaceutical form:Freeze-dried PRP\~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection

  • Biologicalmonovalent Hep B vaccine

    Pharmaceutical form: Depending on the brand procured Route of administration:IM injection

06

What researchers measure

Primary outcomes

  1. 1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):

    Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA

    Time frame: Day181

Secondary outcomes

  1. Baseline, pre-vaccination sample

    Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL * Anti-PRP Ab concentrations ≥0.15 μg/mL * Anti-Hep B Ab concentrations ≥10 mIU/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)

    Time frame: Day 31

  2. 1 month after the last dose of primary series:

    Ab concentrations/titers for each Ag Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-PRP Ab concentrations ≥0.15 μg/mL and ≥1.0 μg/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) * Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL Ab individual concentration/titer ratios for all antigens except for Hep B) (post-Dose 3/pre-Dose 1) Anti-Hep B Ab individual concentration ratio (post-Dose 4 Hep B/pre-Dose 2 Hep B in the investigational group, or post-Dose 3 Hep B/post-Dose 2 Hep B in the comparator group) Note: Dose 1 Hep B corresponds to the dose of Hep B vaccine given at birth.

    Time frame: Day181

  3. Before the booster dose:

    Ab concentrations/titers for each Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) * Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL

    Time frame: Day 511

  4. 1 month after the booster dose:

    Ab concentrations/titers for each Ag of Pentaxim Ab concentrations/titers above a cut-off: * Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL * Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL * Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Seroconversion for anti-PT and anti-FHA defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Booster to post-Booster Ab individual concentration/titer ratios for all antigens (post-Booster/pre-Booster)

    Time frame: Day 541

  5. Presence of immediate unsolicited adverse events (AEs)

    Time frame: 30 minutes after each and any vaccination

  6. Presence of solicited injection site reactions

    (pre-listed in the participant diary and case report form \[CRF\])

    Time frame: for 8 days, including the day of each and any vaccination

  7. Presence of solicited systemic reactions

    (pre-listed in the participant diary and CRF)

    Time frame: for 8 days, including the day of each and any vaccination

  8. Presence of unsolicited AEs

    Time frame: for 30 days, including the day of each and any vaccination

  9. Presence of serious adverse events (SAEs)

    Time frame: up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination

  10. Presence of related SAEs and fatal case regardless of causality

    Time frame: Day 541

  11. Presence of AEs leading to study discontinuation

    Time frame: Day 541

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2028, 15 months later.

Of 47 industry-sponsored phase 3 interventional studies under Diphtheria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's planned 15 months is above that.

Counting every sponsor, half of 47 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 28, 2026
Primary completionEst.
Apr 27, 2028
CompletionEst.
Jul 30, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941622
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 28, 2026 (estimated)
Primary completion
Apr 27, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion